New combo therapy aims to shrink tumors, save breasts
NCT ID NCT06843681
Summary
This study is testing whether a combination of two drugs (trastuzumab and a taxane chemotherapy) given before surgery can effectively shrink tumors in people with a specific type of early breast cancer (HER2-positive). The main goal is to see if this approach allows more patients to have breast-conserving surgery instead of a full mastectomy. Researchers will also monitor how well the treatment works and its side effects in about 54 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.